Selective ‘super-specific’ inhibitors of Protein Phosphatase 1 (PP1) are not available. Several natural product toxins possessing marginal selectivity between PP1 and the closely related Protein Serine/Threonine Phosphatase (PSTP), Protein Phosphatase 2A (PP2A) have been used to study the role of PP1 and PP2A in cellular signaling processes, such as the cyclic peptide inhibitors (microcystins and nodularins); terpenoid (cantharidin); polyketides (okadaic acid, calyculin, and tautomycin). The organic molecule tautomycetin is a natural product which has the highest selectivity for PP1 compared to the closely related PSTP PP2A, albeit slightly so (about 39 times more selective). Calyculin A is equally selective to PP1 and PP2A. On the other hand, okadaic acid is about 100 times more selective towards PP2A compared to PP1. Specific protein inhibitors are not suitable for cell-based assay due to low, intrinsic cellular permeability of proteins. A si-RNA mediated knockdown approach though feasible, is not ‘fast-acting’. The knockdown often lasts for an extended time period and cannot be modulated (turned on or off) as desired. Also, analysis of knockdown data is complex as the system can regulate itself in complex ways, making any effort to interpret the data liable to misinterpretation. The ultimate goal of this project is to develop a cell-permeable, potent, and selective inhibitor for PP1 (which does not target the related protein phosphatases PP2A, PP2B and PP5) whose activity inside cells can be modulated as desired so that spatiotemporal control over the activity of PP1 can be achieved. Development of such an inhibitor can be used as a chemical tool to study the cellular signaling of PP1 and not by the related PSTP PP2A. To address the problem of a lack of inhibitor targeting Protein Phosphatase 1 selectively over the closely related PSTP, PP2A; design of a peptide based inhibitor has been envisioned which targets the acidic groove and hydrophobic groove of Protein Phosphatase 1 in addition to targeting the active site (triple approach combination). The parent peptide (V6.2.10) of this study has been designed using a co-crystal structure of rat PP1cγ complexed with mouse inhibitor-2 (PDB ID: 2O8A). The parent peptide V6.2.10 has an IC50 value of 4.2 µM, which has been confirmed in the present study. A combination of single site mutations has been made using N-terminus arginine scanning, C-terminus arginine scanning, active site mutations, cyclohexylalanine scanning, and miscellaneous site-specific mutations. A hydrophobic pocket present in Protein Phosphatase 1 has been probed using ortho and meta fluorophenyalanine residue to increase potency and metabolic stability of the peptide. The rationale for such mutations was based upon a combination of approaches: mutagenesis in PyMOL, calculation of binding energies in FoldX, suitability of parent residues to be mutated, and how important are parent and substituent residues for cellular permeability and metabolic stability. Several peptides were identified from single-site mutations which had lower (improved) IC50 compared to the parent peptide of the study, V6.2.10. Several double mutations combining potent single-mutant peptides identified from this study has lower (improved) IC50 values than either of the single mutant peptides. #30 (combination of #15 and #4.2) has an IC50 value of about 334 nM and #36 (combination of #15 and 4-Fluoro Phenylalanine at the F5 position) has an IC50 value of 531 nM. #30 is the optimized peptide inhibitor from this study which is currently being utilized for crystallization trails in the laboratory. Far UV Circular dichroism study of #4.2 peptide shows mostly random coil conformation along with contributions from other secondary structures. Moreover, #4.2 is capable of adopting an alpha helical conformation in the presence of the well-known helix inducer chemical trifluoroethanol. Purification of PP1α protein using affinity chromatography has been optimized in order to increase the yield of pure protein phosphatase 1. Attempts to express and purify PP1α protein in BL21 (DE3) bacterial cells gave low yield. Thus, expression and purification of PP1α protein derived from human genomic sequence has been attempted in BL21 (RIL) codon-optimized cells which resulted in increased production of pure protein.

Le paludisme est la première endémie parasitaire mondiale causée par le protozoaire Plasmodium. Cette parasitose est responsable de 219 millions de cas et 660 000 décès par an. La prévalence et la mortalité élevées sont liées notamment à la résistance des parasites aux traitements existants, ce qui rend primordial le développement de nouvelles thérapeutiques. Pour ce faire, une meilleure connaissance de la biologie fondamentale du parasite est nécessaire. Dans ce contexte l’un des axes de recherche concerne la régulation du cycle cellulaire chez Plasmodium et notamment les mécanismes de phosphorylation/déphosphorylation qui sont essentiels.Parmi les nombreux acteurs des mécanismes de phosphorylation, la sérine/thréonine protéine phosphatase de type 2A (PP2A) est, avec PP1, l’une des phosphatases majeures. Cette phosphatase est impliquée dans de nombreux processus cellulaires notamment la mitose, la méiose ou encore l’apoptose. Elle est composée d’une sous-unité catalytique (PP2Ac), d’une sous-unité d’aide à l’agencement spatial (A) et d’une sous-unité régulatrice (B). Il existe quatre familles de sous-unités régulatrices contenant chacune plusieurs membres qui permettent de réguler la localisation, la spécificité et l’activité de PP2A. Il existe également des protéines régulatrices indépendantes, notamment les inhibiteurs 1 et 2, la protéine α4 et le PhosphoTyrosyl Phosphatase Activator (PTPA). Chez Plasmodium falciparum, la protéine phosphatase de type 2A ou PfPP2A a été identifiée et semble essentielle pour le développement asexué du parasite. Cependant, peu de choses sont connues sur sa régulation chez le parasite. En effet, seul l’inhibiteur 2 de PP2A a été décrit et caractérisé. Au cours de cette thèse, nous avons effectué par des études in silico un recensement des régulateurs putatifs de PfPP2A. Ces études nous ont permis d’identifier la sous-unité A et une unique sous-unité B. Parmi les régulateurs spécifiques, outre l’inhibiteur 2 déjà caractérisé, l’analyse du génome du parasite montre qu’il contient un orthologue de l’inhibiteur 1, d’α4 et de PTPA. Le projet de cette thèse s’articule autour de la caractérisation moléculaire et fonctionnelle de l’un de ces régulateurs : PfPTPA.La caractérisation moléculaire de PfPTPA a permis de montrer dans ce travail la conservation de cette protéine au cours de l’évolution. L’analyse de sa séquence a révélé que cinq des six motifs de fixation à la PP2A identifiés chez l’homme sont conservés. Par des études in vitro et in vivo dans un modèle hétérologue, nous avons pu confirmer le rôle d’activateur de PfPTPA vis-à-vis de la PP2A. Par une approche de mutation unique d’acides aminés, nous avons identifié trois résidus impliqués dans l’interaction et l’activité de PfPTPA notamment le résidu G292 qui est essentiel pour l’interaction PfPTPA/PfPP2A. Nous avons ensuite montré par des études de génétique inverse que PfPP2A et PfPTPA, qui sont présents dans le même compartiment cellulaire au cours du cycle érythrocytaire, sont essentielles pour la complétion du cycle intra-érythrocytaire du parasite. De plus, PfPTPA semble impliqué dans le cycle cellulaire chez le xénope.En parallèle, l’analyse de la séquence de PfPTPA, a révélé la présence, spécifique au parasite, d’un motif de fixation à la PP1 (motif RVxF). L’identification de ce motif, nous a incités à étudier la relation entre PfPTPA et PfPP1. Nous avons ainsi pu montrer que PfPTPA était capable de se lier à PfPP1 même si elle est incapable de réguler son activité.L’ensemble de ce travail de thèse a permis de caractériser chez Plasmodium falciparum un activateur de la protéine phosphatase de type 2A et de montrer sa spécificité par rapport à la protéine humaine. Nos résultats, et notamment l’implication de PfPTPA dans la régulation du cycle cellulaire, font de ce régulateur une cible thérapeutique potentielle. / Malaria is the most deadly parasitic disease in the world caused by the Apicomplexa protozoan Plasmodium falciparum. This parasite is responsible for 219 million cases and 660 000 deaths per year and the drug resistance increases the prevalence and the morbidity. The emergence of multi-drug resistance requires the development of new therapeutics. Hence, a better understanding of parasitic fundamental biology is necessary. In this context, one research axis is the cell cycle regulation of Plasmodium, notably phosphorylation/dephosphorylation mechanisms which are essential for the parasite.Among the actors of the reversible phosphorylation, the serine/threonine phosphatase type 2A (PP2A) in eukaryote is, with PP1, one of the major phosphatases. It is involved in several cell processes like mitosis, meiosis or apoptosis. PP2A is composed of a catalytic subunit (PP2Ac), a scaffold subunit (A) and a regulatory subunit (B). There are four regulatory subunit families which regulate location, specificity and activity of PP2A. Furthermore, several independent regulatory proteins including inhibitor 1 and 2, the α4 protein or the phosphotyrosyl phosphatase activator (PTPA) were identified.In Plasmodium falciparum, the protein phosphatase type 2A named PfPP2A has been characterized and seems to be essential for the parasite asexual development as shown by the inhibition of parasitic growth after treatment with natural toxins inhibiting phosphatases. However, its regulation is still poorly understood in Plasmodium. Indeed, only the PP2A inhibitor 2 is characterized in P. falciparum and in P. berghei (a rodent specific Plasmodium species). Using an in silico study, we have identified a putative scaffold subunit and only one B subunit. Among the regulatory proteins, we have identified orthologs of the inhibitor 1, α4 and PTPA. The purpose of this thesis is to study PfPTPA both of the molecular and functional levels.The molecular characterization of PfPTPA showed the evolutionary conservation of this protein. The PfPTPA sequence analysis revealed that five out of six amino acids involved in interaction with PP2A in human, are conserved in P. falciparum. In vitro binding and functional studies revealed that PfPTPA binds to and activates PfPP2A. Mutation studies showed that three residues (V283, G292 and M296) of PfPTPA are indispensable for the interaction and that G292 residue is essential for its activity. Localization studies indicated that PfPTPA and PfPP2A are localized in the same cellular compartment throughout the erythrocytic cycle of P. falciparum, suggesting a possible interaction of both proteins in vivo. In Plasmodium falciparum, genetic studies likely suggested the essentiality of PfPTPA for the completion of intraerythrocytic parasite lifecycle. Functionnal studies, using Xenopus oocyte, showed that PfPTPA blocked the G2/M transition. Further analysis of PfPTPA sequence revealed that PfPTPA, unlike its human counterpart, possess one of the most canonical binding motif to PP1 (RVxF motif). The identification of this RVxF motif led us to study the role PfPTPA on PfPP1. Thus, we have shown that PfPTPA interacts with PfPP1 but was unable to regulate PfPP1 activity in vitro. This work allowed characterizing the PfPTPA, an activator of protein phosphatase type 2A in Plasmodium falciparum and to show some specificities when compared to its human ortholog. Our data which suggest that this regulator could be involved in cell cycle regulation, together with its essentiality for the growth of P. falciparum strongly support the idea to explore it as potential drug target.

The goal of this dissertation research is to determine novel regulatory mechanisms of neurotrophin signaling mediated by protein phosphatase 2A (PP2A). PP2A is a ubiquitous Ser/Thr phosphatase that removes phosphates from proteins to switch their activity on or off. The substrate specificity and subcellular localization of PP2A is determined by almost 20 regulatory subunits that associate with a core dimer built of catalytic and scaffold subunits. Since there are more than 48 possible heterotrimers, studying the function of PP2A poses many challenges. Therefore we have devised a strategy, using scaffold subunit knockdown and mutant replacement, to discern the function of specific families of regulatory subunits. With this approach, I have identified specific PP2A holoenzymes that modulate nerve growth factor (NGF) signaling pathways by positively regulating TrkA receptor tyrosine kinase activity. Many studies have shown that NGF is required for the survival and differentiation of sensory and sympathetic neurons. Additionally, NGF is implicated in many neurodegenerative diseases including Alzheimer's disease, Parkinson's disease as well as neuropathic pain. NGF elicits its biological effect through sustained activity of the TrkA receptor and stimulated signaling cascades, including the MAP kinase pathway. Although PP2A has been shown to modulate the mitogen-activated protein (MAP) kinase pathway both positively and negatively at multiple levels, work described herein introduces yet another level of regulation. Specifically, I have shown that PP2A/B' holoenzymes complex with the TrkA neurotrophin receptor to potentiate receptor tyrosine kinase activity, downstream effector kinase activation, neurite outgrowth, and neuronal differentiation. On the other hand, extracellular signal regulated kinase (ERK), a terminal effector in the MAP kinase pathway was shown to phosphorylate a residue in the juxtamembrane region of TrkA and impose feedback inhibition of receptor activity. Collectively, these data suggest a model in which PP2A and ERK oppose each other in the regulation of TrkA receptor activity and downstream signaling cascades that govern neuronal differentiation and maintenance.

Regulation of class IIa histone deacetylases (HDACs) phosphorylation is crucial because it provides the opportunity to control important developmental processes associated with these key enzymes. Indeed, the transcriptional repressor activity of class IIa HDAC is controlled via their phosphorylation-dependent nucleo-cytoplasmic shuttling. While a lot of efforts have been directed towards the identification of the inactivating kinases that phosphorylate class IIa HDACs, the identity of the antagonist phosphatase remained an open question. During this work, we found that protein phosphatase 2A (PP2A) is responsible for dephosphorylating the class IIa HDACs member HDAC7, thereby regulating its subcellular localization and repressor activity. In order to validate our model, functional consequences of these findings was illustrated during the two main biological processes involving HDAC7, i.e. T-cells apoptosis during negative selection and endothelial cells angiogenic activities during vascular network formation. Cellular PP2A represents a large population of trimeric holoenzymes containing a variable regulatory subunit, whose identity has a crucial role in determining the specificity of PP2A catalytic activity. In an effort to characterize the regulation of HDAC7 dephopshorylation, we identified the relevant PP2A holoenzyme regulating HDAC7 function during vasculogenesis and we found that, among diverse regulatory subunit isoforms, PP2A-Bα uniquely regulates endothelial cell angiogenic properties. PP2A-Bα silencing using small interfering RNAs results in a significant inhibition of endothelial cell tube formation and migration. These results establish PP2A, and more precisely the Bα containg PP2A holoenzyme, as an essential element in the regulation of the class IIa HDAC HDAC7 and unravel a first developmental function for the PP2A regulatory subunit Bα in the genesis of blood vessels.

Thesis (Ph. D.)--Cornell University, May, 2008. / Vita. Includes bibliographical references (leaves 104-122).

No description available.

SRY (sex determining region Y)-box 2 (SOX2) is one the embryonic stem cell transcription factors that is capable of reprogramming adult differentiated cells into an induced pluripotent cell. SOX2 is amplified in various types of epithelial cancers and its high its expression correlates with poor prognosis and decreased patient survival. Aberrant Wnt signaling drives the colo-rectal carcinogenic process and is a major determinant of the disease outcome. This study demonstrates that SOX2 counteracts Wnt driven tumor cell proliferation and maintains quiescence in a sub-population of Colo-Rectal Cancer (CRC) cells. High SOX2 expression is found in a sub-group of CRC patients with advanced disease. High SOX2 expression coupled with low Wnt activity was found in SW620 metastatic CRC cell line, while the opposite was true for the isogenic SW480 primary tumor cell line. SOX2 silencing increased Wnt activity and enhanced the oncogenic potential of SW620 cells in vitro and in vivo while over-expression had opposite effects in SW480 cells. SOX2 up-regulates the expression of PTPRK and PHLPP2 protein phosphatase genes which in turn attenuates Wnt activity by interfering with Protein Kinase A, B and C mediated beta catenin phosphorylation at Serine 552 and 675 amino acid residues thereby diminishing its nuclear sequestration and transcriptional activation. Thus SOX2 mitigates growth factor mediated Wnt activation in CRC cells and inhibits cellular proliferation so that these cells are forced to change their oncogene addiction. In effect, high SOX2 expression causes clonal evolution of APC mutant CRC cells from a state of high Wnt dependency to a state of low Wnt dependency in the process making such cells resistant to Wnt inhibitor therapy. Enhanced SOX2 transcriptional activity was associated with increased proportion of cancer cells in G0-G1 phase of cell cycle. Changing SOX2 protein levels in cells had a direct correlation with mRNA levels of RBL2-HUMAN and CDKN2B genes, which serve as regulators of G0 and G1 respectively. SOX2 was shown to physically bind and to the promoter region of these two genes and enhance their transcription. Thus high SOX2 expression, up-regulates the expression of key cell cycle inhibitor genes like RBL2 and CDKN2B and keeps cells in a dormant state. This phenomenon allows colon cancer cells to escape from cytotoxic drug therapy directed at rapidly dividing cells and cause treatment failure and disease relapse.

No description available.

No description available.

Aims Protein Phosphatase Inhibitor 1 (I-1) functions as an amplifier of the β-adrenergic cascade in cardiomyocytes. Once activated via PKA, I-1 specifically blocks PP-1-mediated dephosphorylation of phospholamban and the ryanodine receptor-1. In heart failure I-1 activity as well as its expression is significantly reduced. It is still unclear whether this adaptation is protective or detrimental. This work aims at examining the impact of I-1 depletion on the course of pressure-induced heart failure, more precisely on acute and long-term mortality, on cardiac morphology and function and on expression levels of hypertrophy markers. Results may help evaluating the benefit of putative I-1 inhibiting substances in the therapy of heart failure. Methods and Results 25 I-1KO and 28 WT mice (C57Bl/6J, age- and sex-matched) underwent transverse aortic constriction (TAC). Cardiac function was assessed via transthoracic echocardiography prior to the intervention and weekly afterwards. Additionally, mice were exposed to β-adrenergic stimulation by injection of dobutamine once prior to TAC and two times afterwards, each controlled by echocardiography. For male mice acute survival was significantly increased in WT compared to I-1KO, whereas the mortality of surviving animals did not differ during the investigation period. For female mice no difference was seen in acute mortality after TAC, but during heart failure progression I-1KO revealed a significantly better survival. Prior to TAC contractility in I-1KO after application of dobutamine was significantly lower than in WT. This effect was mainly induced by female mice. Overall female mice of both WT and I-1KO showed smaller increases in heart rate (HR) and stroke volume (SV) when stimulated. In contrast, following TAC neither line- nor sex-dependent differences were found according to β-adrenergic stimulation. The comparison of hypertrophy markers in control groups revealed clearly decreased levels for I-1KO compared to WT. Conclusion In pressure-induced heart failure, I-1 knockout alters cardiac contractility and modulates mortality in a phase- and sex-dependent way. The depletion is detrimental for male mice in the acute phase of cardiac stress, whereas it is protective for female mice during heart failure progression. The increased mortality in the acute phase might result from the loss of I-1 as an amplifier of β-adrenergic signaling as this leads to a restriction of contractile adaptation. The increased survival in heart failure progression might be caused by a reduced transmission of pathologically increased sympathetic activity on the SR due to the depletion of I-1. Additionally, hypertrophy marker analyses point to differences in expression levels even under non-pathological conditions. / Ziel Der Proteinphosphatase-Inhibitor I-1 wirkt als ein Verstärker der β-adrenergen Kaskade in Kardiomyozyten. Nach PKA-abhängiger Phosphorylierung hemmt er spezifisch die Dephosphorylierung von PLB und RYR-2 durch die Proteinphosphatase-1. Im Rahmen einer Herzinsuffizienz sind sowohl Aktivität als auch Expression von I-1 deutlich reduziert. Hierbei ist unklar, ob dies eine protektive oder eine schädliche Adaption der β-adrenergen Kaskade darstellt. Diese Arbeit untersucht den Einfluss einer Depletion des I-1 (I-1KO) im Rahmen der druckinduzierten Herzinsuffizienz auf die akute bzw. auf die langfristige Mortalität, auf die kardiale Morphologie und Funktion sowie auf die Expression typischer Hypertrophiemarker. Hieraus sollen Erkenntnisse über den Nutzen der Verwendung putativ I-1 inhibierender Substanzen in der Behandlung der Herzinsuffizienz gewonnen werden. Methoden und Resultate 25 I-1KO- sowie 28 WT-Mäuse (C57Bl/6J, age and sex matched) erhielten eine Transverse Aortic Constriction (TAC). Die kardiale Funktion wurde einmalig vor der Intervention sowie danach wöchentlich mittels TTE untersucht. Zusätzlich wurden die Tiere einmalig vor TAC und zweimalig danach unter echokardiographischer Kontrolle mittels Dobutamin β-adrenerg stimuliert. Für die männlichen Tiere zeigte sich in den ersten Tagen nach TAC eine signifikant erhöhte Überlebensrate des WT gegenüber I-1KO. Die Mortalität der überlebenden männlichen Tiere unterschied sich hingegen nicht über den Versuchszeitraum. Für die weiblichen Tiere bestand kein Unterschied in der akuten Sterblichkeit nach TAC, während sich im Verlauf eine signifikant bessere Überlebensrate der weiblichen I-1KO gegenüber WT zeigte. Vor TAC wurde eine signifikant herabgesetzte Kontraktilität (FAS) des I-1KO unter Dobutamin festgestellt, der im Wesentlichen durch die weiblichen Tiere bewirkt wird. Insgesamt zeigten die weiblichen Tiere beider Linien unter β-adrenerger Stimulation eine geringere Zunahme von Herzfrequenz (HR) und Schlagvolumen (SV). Hingegen waren nach TAC keine linien- oder geschlechtsabhängigen Unterschiede unter Dobutamingabe feststellbar. Ein Vergleich der Hypertrophiemarker in der Kontrollgruppe zeigte für I-1KO ein deutlich vermindertes Niveau der Marker gegenüber WT. Ergebnis Der I-1-Knockout verändert die kardiale Kontraktilität und wirkt sowohl in phasen- als auch in geschlechtsabhängiger Weise auf die Mortalität infolge druckinduzierter Herzinsuffizienz. Er ist nachteilig für männliche Tiere in der akuten Phase kardialer Belastung, während er für weibliche Tiere im weiteren Verlauf protektive Wirkung entfaltet. Eine erhöhte Mortalität in der akuten Phase kann durch den Ausfall der Verstärkerfunktion des I-1 erklärt werden, da hiermit eine Einschränkung der akut notwendigen kontraktilen Adaptionsfähigkeit einhergeht. Ein Überlebensvorteil bei chronischer kardialer Belastung könnte darauf zurückzuführen sein, dass die pathologisch erhöhte sympathische Aktivierung der β-adrenergen Kaskade infolge der I-1-Depletion eine geringere Auswirkung auf die Zielstrukturen des aktivierten I-1 am Sarkoplasmatischen Retikulum hat. Darüber hinaus lassen die Analysen der Hypertrophiemarker eine veränderte Genexpression zwischen I-1KO und WT auch unter nicht-pathologischen Bedingungen vermuten.